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Figure 2. Disease-Specific 
Control Rates by Category 1
Treatment. Determined by 
eliminating patients that 
expired due to other 
causes and accounting for 
both alive & expired
patients with disease
control.
Figure 3. Current status of patients 
who were smokers at time of diagnosis. 
The majority of all patients (66%) 
diagnosed with Stage II or Stage III 





























• Every year, approximately 80,670 people are diagnosed 
with bladder cancer with 90% over the age of 55 and the 
majority of them men1,2
• This study focused on Stage II and Stage III bladder cancer
• 2019 NCCN Guidelines define Category 1 Treatments for 
Stage II & Stage III to be neoadjuvant cisplatin-based 
chemotherapy and radical cystectomy OR concurrent 
chemoradiotherapy3
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protocol was in 
accordance
with the 2019 
NCCN 
Guidelines.
• When compared to the 2019 NCCN Guidelines, Category 1 
Treatment was administered to 50% of Stage II patients and 46%
of Stage III patients at LVHN
– All exceptions to this practice were justified by patient 
preference and/or comorbidities present
• Surgery + Chemotherapy had the highest disease-specific 
control rate
• 66% of bladder cancer patients were current or former smokers
• Age at Diagnosis
– ACSO Mean Age: 73 years1
– LVHN Age Range: 49-94 years; Mean: 75 years
• Gender
– ACSO: 77% male, 23% female1
– LVHN: 74% male, 26% female
• Category 1 Treatment Use
– Surgery + Chemo: Stage II - 26.2%; Stage III - 36.4%
– Chemo + RT: Stage II – 23.8%; Stage III – 9.1%
• Cases were examined for: Date of Diagnosis, Age at 
Diagnosis, Staging, Gender, Treatment Modalities, Survival 








Overall Survival Status, Stage III
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Figure 1. Overall Survival Status of Patients Diagnosed with Stage II (L) and Stage III (R)
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